Most Read

Silence received a notice of intention to grant from the European Patent Office for patent application EP 3 222 724B, further strengthening its innovative chemical modification technology patent

The collaboration will leverage Jnana’s proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine’s research and development expertise in CNS disorders to advance

Designed to Current Good Manufacturing Practices (cGMP) specifications and certified by the Belgian Federal Agency for Medicines and Healthcare Products, the new €5m facility, adjacent to its headquarters

The two studies are projected to deliver a total of c.£9m in revenue, with most of the revenue being recognised in 2019. These contracts are in addition to

Hemlibra is now the only prophylactic treatment for people with haemophilia A with and without factor VIII inhibitors that can be administered subcutaneously (under the skin) and at

Merck has announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to Delstrigo , a once-daily fixed-dose combination tablet of

In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of abacavir/dolutegravir/lamivudine (600/50/300mg, ABC/DTG/3TC) through 96 weeks of therapy. The data will be presented

ALN-AAT02 is Alnylam’s first investigational RNAi therapeutic utilizing the Company’s enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology. Alnylam ALN-AAT02 program lead vice president Thomas Hoock said: “We are

Kite and HiFiBiO intend to adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR